Sclerostin: a possible target for the management of cancer-induced bone disease

Author： Gkotzamanidou Maria Dimopoulos Meletios A Kastritis Efstathios Christoulas Dimitrios Moulopoulos Lia A Terpos Evangelos

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.16, Iss.8, 2012-08, pp. : 761-769

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dickkopf-1: a suitable target for the management of myeloma bone disease

By Gavriatopoulou Maria Dimopoulos Meletios-Athanasios Christoulas Dimitrios Migkou Magdalini Iakovaki Marina Gkotzamanidou Maria Terpos Evangelos

Expert Opinion on Therapeutic Targets, Vol. 13, Iss. 7, 2009-07 ,pp. : 839-848

Informa Healthcare

Access to resources Recommend Favorite

Optimal Management of Cancer Treatment-Induced Bone Loss: Considerations for Elderly Patients

By Tipples Karen Robinson Anne

Drugs & Aging, Vol. 28, Iss. 11, 2011-11 ,pp. : 867-883

Adis International

Access to resources Recommend Favorite

Emerging drugs for the management of cancer treatment induced bone loss

By Bertoldo Francesco Pancheri Serena Zenari Sonia Boldini Stefania

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 2, 2010-06 ,pp. : 323-342

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease

By Dawson Nancy A

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 5, 2003-05 ,pp. : 705-716

Informa Healthcare

Access to resources Recommend Favorite

Pamidronate: A Review of its Use in the Management of Osteolytic Bone Metastases, Tumour-Induced Hypercalcaemia and Paget's Disease of Bone

By Coukell A.J. Markham A.

Drugs & Aging, Vol. 12, Iss. 2, 1998-02 ,pp. : 149-168

Adis International

Access to resources Recommend Favorite